Adherence, adverse drug reactions, and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: a meta-analysis based on cohort studies

References

• Global HIV & AIDS statistics.—2022 fact sheet | UNAIDS, https://www.unaids.org/en/resources/fact-sheet. Accessed 12 March 2023.
   Google Scholar
• Pai NP, Karellis A, Kim J, et al. Modern diagnostic technologies for HIV. Lancet HIV. 2020;7(8):1–13. doi: 10.1016/S2352-3018(20)30190-9.
   Web of Science ®Google Scholar
• Logie CH, Wang Y, Lalor P, et al. Pre and post-exposure prophylaxis awareness and acceptability among sex workers in Jamaica: a cross-sectional study. AIDS Behav. 2021;25(2):330–343. doi: 10.1007/s10461-020-02972-5.
   PubMed Web of Science ®Google Scholar
• Heendeniya A, Bogoch II. Antiretroviral medications for the prevention of HIV infection: a clinical approach to preexposure prophylaxis, postexposure prophylaxis, and treatment as prevention. Infect Dis Clin North Am. 2019;33(3):629–646. doi: 10.1016/j.idc.2019.04.002.
   PubMed Web of Science ®Google Scholar
• Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145719., accessed 1 June 2023).
   Google Scholar
• Kuhar DT, Henderson DK, Struble KA, et al. Updated US public health service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875–892. doi: 10.1086/672271.
   PubMed Web of Science ®Google Scholar
• Announcement: updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV - United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(17):458.
   PubMedGoogle Scholar
• Public health service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for disease control and prevention. MMWR Recomm Rep. 1998;47(Rr-7):1–33.
   Google Scholar
• Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of health and human services. MMWR Recomm Rep. 2005;54(Rr-2):1–20.
   PubMedGoogle Scholar
• Shipeolu L, Sampsel K, Reeves A, et al. HIV nonoccupational postexposure prophylaxis for sexual assault cases: a 3-year investigation. AIDS. 2020;34(6):869–876. doi: 10.1097/QAD.0000000000002507.
   PubMed Web of Science ®Google Scholar
• Sultan B, Benn P, Waters L. Current perspectives in HIV post-exposure prophylaxis. HIV AIDS. 2014;6:147–158. doi: 10.2147/HIV.S46585.
   Google Scholar
• Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72(5):4265–4273. doi: 10.1128/JVI.72.5.4265-4273.1998.
   PubMed Web of Science ®Google Scholar
• Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis. 2005;41(10):1507–1513. doi: 10.1086/497268.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30. doi: 10.7326/0003-4819-133-1-200007040-00004.
   PubMed Web of Science ®Google Scholar
• Bryant J, Baxter L, Hird S. Non-occupational postexposure prophylaxis for HIV: a systematic review. Health Technol Assess. 2009;13(14):iii, ix-x, :1–60. doi: 10.3310/hta13140.
   Web of Science ®Google Scholar
• Devine F, Edwards T, Feldman SR. Barriers to treatment: describing them from a different perspective. Patient Prefer Adherence. 2018;12:129–133. doi: 10.2147/PPA.S147420.
   PubMed Web of Science ®Google Scholar
• Kvarnström K, Airaksinen M, Liira H. Barriers and facilitators to medication adherence: a qualitative study with general practitioners. BMJ Open. 2018;8(1):e015332. doi: 10.1136/bmjopen-2016-015332.
   PubMed Web of Science ®Google Scholar
• Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35(5):519–525. doi: 10.1097/00126334-200404150-00010.
   PubMed Web of Science ®Google Scholar
• Garcia MT, Figueiredo RM, Moretti ML, et al. Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Transm Dis. 2005;32(4):214–219. doi: 10.1097/01.olq.0000149785.48574.3e.
   PubMed Web of Science ®Google Scholar
• Gupta A, Anand S, Sastry J, et al. High risk for occupational exposure to HIV and utilization of post-exposure prophylaxis in a teaching hospital in pune, India. BMC Infect Dis. 2008;8:142. doi: 10.1186/1471-2334-8-142.
   PubMed Web of Science ®Google Scholar
• Rey D, Bendiane MK, Bouhnik A-D, et al. Physicians’ and patients’ adherence to antiretroviral prophylaxis after sexual exposure to HIV: results from South-Eastern France. Aids Care. 2008;20(5):537–541. doi: 10.1080/09540120701867198.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhu Q, Zhou Y, et al. Implementation of HIV non-occupational post-exposure prophylaxis for men who have sex with men in 2 cities of Southwestern China Medicine. 2021;100(43):e27563. doi: 10.1097/MD.0000000000027563.
   PubMed Web of Science ®Google Scholar
• Mushambi F, Timire C, Harries AD, et al. High post-exposure prophylaxis uptake but low completion rates and HIV testing follow-up in health workers, Harare, Zimbabwe. J Infect Dev Ctries. 2021;15(4):559–565. doi: 10.3855/jidc.12214.
   PubMed Web of Science ®Google Scholar
• Gantner P, Hessamfar M, Souala MF, et al. Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. Clin Infect Dis. 2020;70(5):943–946.
   PubMed Web of Science ®Google Scholar
• Tosini W, Muller P, Prazuck T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS. 2010;24(15):2375–2380. doi: 10.1097/QAD.0b013e32833dfad1.
   PubMed Web of Science ®Google Scholar
• Lee LM, Henderson DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf. 2001;24(8):587–597. doi: 10.2165/00002018-200124080-00003.
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Macdonald S, Myhr T, et al. Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors. Antivir Ther. 2008;13(1):87–95. doi: 10.1177/135965350801300109.
   PubMed Web of Science ®Google Scholar
• Nie J, Sun F, He X, et al. Tolerability and adherence of antiretroviral regimens containing Long-Acting fusion inhibitor albuvirtide for HIV post-exposure prophylaxis: a cohort study in China Infect Dis Ther. 2021;10(4):2611–2623. doi: 10.1007/s40121-021-00540-5.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. doi: 10.1136/bmj.g7647.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea BO, O’Connell D, et al. The Newcastle‑Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta‑Analyses. Ottawa, ON: Ottawa Hospital Research Institute; 2000. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 15 February 2023.
   Google Scholar
• Bispo S, Chikhungu L, Rollins N, et al. Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis. J Int AIDS Soc. 2017;20(1):21251. doi: 10.7448/IAS.20.1.21251.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yuan T, Fan S, et al. HIV nonoccupational postexposure prophylaxis among men who have sex with men: a systematic review and meta-analysis of global data. AIDS Patient Care STDS. 2020;34(5):193–204. doi: 10.1089/apc.2019.0313.
   PubMed Web of Science ®Google Scholar
• Lemma T, Silesh M, Taye BT, et al. HIV serostatus disclosure and its predictors among children living with HIV in Ethiopia: a systematic review and meta-analysis. Front Public Health. 2022;10:859469. doi: 10.3389/fpubh.2022.859469.
   PubMed Web of Science ®Google Scholar
• Linden JA, Oldeg P, Mehta SD, et al. HIV postexposure prophylaxis in sexual assault: current practice and patient adherence to treatment recommendations in a large urban teaching hospital. Acad Emerg Med. 2005;12(7):640–646. doi: 10.1197/j.aem.2005.01.015.
   PubMed Web of Science ®Google Scholar
• Winston A, McAllister J, Amin J, et al. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis. HIV Med. 2005;6(3):191–197. doi: 10.1111/j.1468-1293.2005.00288.x.
   PubMed Web of Science ®Google Scholar
• Day S, Mears A, Bond K, et al. Post-exposure HIV prophylaxis following sexual exposure: a retrospective audit against recent draft BASHH guidance. Sex Transm Infect. 2006;82(3):236–237. doi: 10.1136/sti.2005.017764.
   PubMed Web of Science ®Google Scholar
• Shoptaw S, Rotheram-Fuller E, Landovitz RJ, et al. Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention. Aids Care 2008;20(3):376–381. doi: 10.1080/09540120701660353.
   PubMed Web of Science ®Google Scholar
• Lunding S, Katzenstein TL, Kronborg G, et al. The Danish PEP registry: experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006. Sex Transm Dis. 2010;37(1):49–52. doi: 10.1097/OLQ.0b013e3181b6f284.
   PubMed Web of Science ®Google Scholar
• Tissot F, Erard V, Dang T, et al. Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis. HIV Med. 2010;11(9):584–592. doi: 10.1111/j.1468-1293.2010.00826.x.
   PubMed Web of Science ®Google Scholar
• Wong K, Hughes CA, Plitt S, et al. HIV non-occupational postexposure prophylaxis in a Canadian province: treatment completion and follow-up testing. Int J STD AIDS. 2010;21(9):617–621. doi: 10.1258/ijsa.2008.008482.
   PubMed Web of Science ®Google Scholar
• Shevkani M, Kavina B, Kumar P, et al. An overview of post exposure prophylaxis for HIV in health care personals: Gujarat scenario. Indian J Sex Transm Dis AIDS. 2011;32(1):9–13. doi: 10.4103/0253-7184.81247.
   PubMedGoogle Scholar
• Mayer KH, Mimiaga MJ, Gelman M, et al. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59(4):354–359. doi: 10.1097/QAI.0b013e31824a03b8.
   PubMed Web of Science ®Google Scholar
• Chan ACH, Gough K, Yoong D, et al. Non-occupational post-exposure prophylaxis for HIV at St michael’s hospital, toronto: a retrospective review of patient eligibility and clinical outcomes. Int J STD AIDS. 2013;24(5):393–397. doi: 10.1177/0956462412472826.
   PubMed Web of Science ®Google Scholar
• Gulholm T, Jamani S, Poynten IM, et al. Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual health clinic. Sex Health. 2013;10(5):438–441. doi: 10.1071/SH13018.
   PubMed Web of Science ®Google Scholar
• Bogoch II, Scully EP, Zachary KC, et al. Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis. Clin Infect Dis. 2014;58(11):1618–1624. doi: 10.1093/cid/ciu118.
   PubMed Web of Science ®Google Scholar
• Cai J, Xiao J, Zhang Q. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients. Chin Med. 2014;127(14):2632–2636.
   Google Scholar
• Krause KH, Lewis-O’Connor A, Berger A, et al. Current practice of HIV postexposure prophylaxis treatment for sexual assault patients in an emergency department. Womens Health Issues. 2014;24(4):E407–e412. doi: 10.1016/j.whi.2014.04.003.
   PubMed Web of Science ®Google Scholar
• Tetteh RA, Nartey ET, Lartey M, et al. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu teaching hospital in accra, Ghana. BMC Public Health. 2015;15(1):573. doi: 10.1186/s12889-015-1928-6.
   PubMedGoogle Scholar
• Thomas R, Galanakis C, Vézina S, et al. Adherence to post-exposure prophylaxis (PEP) and incidence of HIV seroconversion in a major North American cohort. PLOS One. 2015;10(11):e0142534. doi: 10.1371/journal.pone.0142534.
   PubMed Web of Science ®Google Scholar
• Ford N, Irvine C, Shubber Z, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS. 2014;28(18):2721–2727. doi: 10.1097/QAD.0000000000000505.
   PubMed Web of Science ®Google Scholar
• Fusca L, Hull M, Ross P, et al. High interest in syphilis pre-exposure and post-exposure prophylaxis among gay, bisexual and other men who have sex with men in vancouver and toronto. Sex Transm Dis. 2020;47(4):224–231. doi: 10.1097/OLQ.0000000000001130.
   PubMed Web of Science ®Google Scholar
• Zhou L, Assanangkornchai S, Shi Z, et al. Acceptability of pre-exposure prophylaxis and non-occupational post-exposure prophylaxis among men who have sex with men in guilin. China. Int J Environ Res Public Health. 2022;19(6):3579. doi: 10.3390/ijerph19063579.
   Google Scholar
• Parkin JM, Murphy M, Anderson J, et al. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet. 2000;355(9205):722–723. doi: 10.1016/s0140-6736(99)05005-9.
   PubMed Web of Science ®Google Scholar
• Neu N, Heffernan-Vacca S, Millery M, et al. Postexposure prophylaxis for HIV in children and adolescents after sexual assault: a prospective observational study in an urban medical center. Sex Transm Dis. 2007;34(2):65–68. doi: 10.1097/01.olq.0000225329.07765.d8.
   PubMed Web of Science ®Google Scholar
• Chacko L, Ford N, Sbaiti M, et al. Adherence to HIV post-exposure prophylaxis in victims of sexual assault: a systematic review and meta-analysis. Sex Transm Infect. 2012;88(5):335–341. doi: 10.1136/sextrans-2011-050371.
   PubMed Web of Science ®Google Scholar
• Oldenburg CE, Bärnighausen T, Harling G, et al. Adherence to post-exposure prophylaxis for non-forcible sexual exposure to HIV: a systematic review and meta-analysis. AIDS Behav. 2014;18(2):217–225. doi: 10.1007/s10461-013-0567-0.
   PubMed Web of Science ®Google Scholar
• Muriuki EM, Kimani J, Machuki Z, et al. Sexual assault and HIV postexposure prophylaxis at an urban african hospital. AIDS Patient Care STDS. 2017;31(6):255–260. doi: 10.1089/apc.2016.0274.
   PubMed Web of Science ®Google Scholar
• Inciarte A, Leal L, Masfarre L, et al. Post-exposure prophylaxis for HIV infection in sexual assault victims. HIV Med. 2020;21(1):43–52. doi: 10.1111/hiv.12797.
   PubMed Web of Science ®Google Scholar
• Krakower DS, Jain S, Mayer KH. Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis. Curr HIV/AIDS Rep. 2015;12(1):127–138. doi: 10.1007/s11904-014-0253-5.
   PubMed Web of Science ®Google Scholar
• Malinverni S, Gennotte AF, Schuster M, et al. Adherence to HIV post-exposure prophylaxis: a multivariate regression analysis of a 5 years prospective cohort. J Infect. 2018;76(1):78–85. doi: 10.1016/j.jinf.2017.10.008.
   PubMed Web of Science ®Google Scholar
• Kim JC, Askew I, Muvhango L, et al. Comprehensive care and HIV prophylaxis after sexual assault in rural South Africa: the refentse intervention study. BMJ. 2009;338(1):b515–b515. doi: 10.1136/bmj.b515.
   PubMedGoogle Scholar
• Roland ME. A model for communitywide delivery of postexposure prophylaxis after potential sexual exposure to HIV. Sex Transm Dis. 2007;34(5):294–296. doi: 10.1097/01.olq.0000258321.62272.0e.
   PubMed Web of Science ®Google Scholar
• Arend E, Maw A, de Swardt C, et al. South African sexual assault survivors’ experiences of post-exposure prophylaxis and individualized nursing care: a qualitative study. J Assoc Nurses AIDS Care. 2013;24(2):154–165. doi: 10.1016/j.jana.2012.02.007.
   PubMed Web of Science ®Google Scholar
• Cooley LA, Hoots B, Wejnert C, et al. Policy changes and improvements in health insurance coverage among MSM: 20 U.S. Cities, 2008-2014. AIDS Behav. 2017;21(3):615–618. doi: 10.1007/s10461-016-1567-7.
   PubMed Web of Science ®Google Scholar
• Stiakaki E, Savvas S, Lydaki E, et al. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol. 1999;16(2):101–108.
   PubMed Web of Science ®Google Scholar
• Currow DC, Coughlan M, Fardell B, et al. Use of ondansetron in palliative medicine. J Pain Symptom Manage. 1997;13(5):302–307. doi: 10.1016/s0885-3924(97)00079-1.
   PubMed Web of Science ®Google Scholar
• Lu TY, Mao X, Peng EL, et al. [Bibliometric analysis on research hotspots on HIV post-exposure prophylaxis related articles in the world, 2000–2017]. Zhonghua Liu Xing Bing Xue Za Zhi. 2018;39(11):1501–1506.
   PubMedGoogle Scholar
• Zablotska IB, Prestage G, Holt M, et al. Australian gay men who have taken nonoccupational postexposure prophylaxis for HIV are in need of effective HIV prevention methods. J Acquir Immune Defic Syndr. 2011;58(4):424–428. doi: 10.1097/QAI.0b013e318230e885.
   PubMed Web of Science ®Google Scholar
• Jain S, Krakower DS, Mayer KH. The transition from postexposure prophylaxis to preexposure prophylaxis: an emerging opportunity for biobehavioral HIV prevention. Clin Infect Dis. 2015;60 S(Suppl 3):S200–S4. doi: 10.1093/cid/civ094.
   Google Scholar
• Benn PD, Mercey DE, Brink N, et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet. 2001;357(9257):687–688. doi: 10.1016/S0140-6736(00)04139-8.
   PubMed Web of Science ®Google Scholar
• Leal L, León A, Torres B, et al. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob Chemother. 2016;71(7):1987–1993. doi: 10.1093/jac/dkw049.
   PubMed Web of Science ®Google Scholar
• Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis. 2004;39(3):395–401. doi: 10.1086/422459.
   PubMed Web of Science ®Google Scholar
• Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240031593., accessed 1 June 2023).
   Google Scholar